AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38365502 — intervention group
Group type: COMPARATOR
Intervention: CT-P13 IV (5 mg/kg Q8W; W6-22) then CT-P13 SC (Q2W; W30-54)
Number of subjects: 112
Study 38365595 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended point-of-care technology (focused lung ultrasound scan and bedside venous blood analysis) in addition to usual care
Number of subjects: 632
Study 38365595 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 632
Study 38365656 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on tobacco control programs
Number of subjects: 46
Study 38365694 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using 980 nm diode laser, 300 mW, twice weekly for 5 weeks (10 sessions)
Number of subjects: 44
Study 38365694 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.1% triamcinolone acetonide three times daily with miconazole oral gel once daily for 4 weeks
Number of subjects: 44
Study 38365719 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual sedentary time
Number of subjects: 119
Study 38365719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged sedentary time
Number of subjects: 119
Study 38365744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors
Number of subjects: 60
Study 38365744 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study 38365758 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Shift video game intervention (2 hours within 2 weeks of enrollment and 20 minutes quarterly)
Number of subjects: 800
Study 38365758 — intervention group
Group type: COMPARATOR
Intervention: Usual education and training (control)
Number of subjects: 800
Study 38365814 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of vancomycin targeting an AUC24h of 400 to 600 mg × h/L
Number of subjects: 0
Study 38365814 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care dosing and monitoring according to institutional guidelines
Number of subjects: 0
Study 38365814 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of vancomycin
Number of subjects: 0
Study 38365820 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR clinician reminder sent to providers prior to scheduled visits
Number of subjects: 368
Study 38365820 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-visit phone-based educational session conducted by an inreach specialist
Number of subjects: 368
Study 38365820 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of provider-patient discussion, screening intentions, and knowledge at baseline and 1-week post-visit
Number of subjects: 368
Study 38365820 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of screening referrals and screening completion rates via EHR at 6 months
Number of subjects: 368
Study 38365820 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods and multilevel assessments of patients and providers
Number of subjects: 368
Study 38365853 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i) treatment for 12 weeks
Number of subjects: 68
Study 38365949 — intervention group
Group type: EXPERIMENTAL
Intervention: ganfeborole 5 mg
Number of subjects: 75
Study 38365949 — intervention group
Group type: EXPERIMENTAL
Intervention: ganfeborole 15 mg
Number of subjects: 75
Study 38365949 — intervention group
Group type: EXPERIMENTAL
Intervention: ganfeborole 30 mg
Number of subjects: 75
Study 38365949 — intervention group
Group type: EXPERIMENTAL
Intervention: ganfeborole 1 mg
Number of subjects: 75
Study 38365949 — intervention group
Group type: COMPARATOR
Intervention: standard of care (Rifafour e-275 or generic alternative)
Number of subjects: 75
Study 38365951 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby program (anxiety-focused cognitive behavioral therapy, six one-on-one sessions)
Number of subjects: 755
Study 38365951 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care alone (control group)
Number of subjects: 755
Study 38365952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose osocimab
Number of subjects: 704
Study 38365952 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose osocimab
Number of subjects: 704
Study 38365952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 38366021 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling with large targeted assay (>300 genes, TMB, MSI status)
Number of subjects: 102
Study 38366021 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling on FFPE samples
Number of subjects: 102
Study 38366021 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular profiling on ctDNA
Number of subjects: 102
Study 38366021 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB advised molecular-guided treatment options
Number of subjects: 102
Study 38366021 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular testing and MTB discussion
Number of subjects: 102
Study 38366225 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of small and ultrasmall graphene oxide nanosheets at a concentration of 200 μg/m3
Number of subjects: 0
Study 38366225 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 38366267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (2.5/5/7.5 or 10 mg/day)
Number of subjects: 38
Study 38366324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 μg
Number of subjects: 60
Study 38366324 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (fentanyl 100 μg and lidocaine 80 mg)
Number of subjects: 60
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoconversion to Parkinson's disease (PD)
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoconversion to dementia with Lewy bodies (DLB)
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoconversion to multiple system atrophy (MSA)
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary dysfunction
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual dysfunction
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle motor signs
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trouble swallowing
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in speech
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration of handwriting
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty handling utensils
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age of PAF onset
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved olfaction
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhidrosis
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe urinary problems
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunted heart rate increase during tilt-table test
Number of subjects: 209
Study 38366572 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual risk of phenoconversion to CNS synucleinopathy
Number of subjects: 209
Study 38366591 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT166a (quadrivalent vaccine)
Number of subjects: 0
Study 38366591 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT166c (trivalent vaccine)
Number of subjects: 0
Study 38366591 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT166a and BNT166c (both vaccines)
Number of subjects: 0
Study 38366621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 665
Study 38366621 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 665
Study 38366621 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (in treatment-naïve subpopulation)
Number of subjects: 665
Study 38366621 — intervention group
Group type: COMPARATOR
Intervention: TNFi (in treatment-naïve subpopulation)
Number of subjects: 665
Study 38366672 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 57
Study 38366672 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 57
Study 38366672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 38366675 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal massage and palm fisting
Number of subjects: 72
Study 38366675 — intervention group
Group type: COMPARATOR
Intervention: Standard care for PVC
Number of subjects: 72
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-treated women with PCOS (n=180)
Number of subjects: 365
Study 38366810 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated women with PCOS (n=185)
Number of subjects: 365
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS (n=131)
Number of subjects: 365
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy complications
Number of subjects: 365
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 365
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of labor
Number of subjects: 365
Study 38366810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 365
Study 38366824 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/MRI post 2 cycles (PET2)
Number of subjects: 65
Study 38366824 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI2 response
Number of subjects: 65
Study 38366886 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus toripalimab (250 mg apatinib per day plus 240 mg toripalimab on day 1 per 3 weeks)
Number of subjects: 51
Study 38366886 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PC)
Number of subjects: 51
Study 38366909 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (2 × 10^6 cells)
Number of subjects: 0
Study 38366909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose group (20 × 10^6 cells)
Number of subjects: 0
Study 38366909 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (80 × 10^6 cells)
Number of subjects: 0
Study 38367032 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt and butter
Number of subjects: 30
Study 38367032 — intervention group
Group type: COMPARATOR
Intervention: Full-fat yogurt
Number of subjects: 30
Study 38367207 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week timing and coordination physical therapy intervention
Number of subjects: 42
Study 38367207 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 42
Study 38367405 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment modified Glasgow prognostic score (mGPS) assessed at week six in atezolizumab-treated subgroup
Number of subjects: 750
Study 38367405 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment modified Glasgow prognostic score (mGPS)
Number of subjects: 750
Study 38367595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Low-No Carbohydrates (SL-NCHO)
Number of subjects: 42
Study 38367595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep High-Low Glycemic Index (SH-LGI)
Number of subjects: 42
Study 38367595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep High-High Glycemic Index (SH-HGI)
Number of subjects: 42
Study 38367643 — intervention group
Group type: EXPERIMENTAL
Intervention: solar-powered O
Number of subjects: 2405
Study 38367686 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfluidics sperm processing
Number of subjects: 106
Study 38367686 — intervention group
Group type: COMPARATOR
Intervention: Density gradient centrifugation
Number of subjects: 106
Study 38367687 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 1212
Study 38367687 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 1212
Study 38367749 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniotomy (rupture of membranes within 2 hours after Foley balloon removal)
Number of subjects: 149
Study 38367749 — intervention group
Group type: COMPARATOR
Intervention: Delayed amniotomy (rupture of membranes performed more than 4 hours after Foley balloon removal)
Number of subjects: 149
Study 38367750 — intervention group
Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol
Number of subjects: 180
Study 38367750 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol
Number of subjects: 180
Study 38367750 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg vaginal misoprostol (subgroup: multiparous patients)
Number of subjects: 180
Study 38367750 — intervention group
Group type: COMPARATOR
Intervention: 25 μg vaginal misoprostol (subgroup: multiparous patients)
Number of subjects: 180
Study 38367750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (25 μg and 50 μg)
Number of subjects: 180
Study 38367767 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing racial discrimination
Number of subjects: 344
Study 38367831 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bedside cycling in addition to inpatient cardiac rehabilitation (CR) program
Number of subjects: 31
Study 38367968 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCORAL programme follow-up
Number of subjects: 216
Study 38367968 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 38367966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge intervention consisting of three text message reminders with four behavioural nudges: (1) social norm messages, (2) different messengers through links to short educational videos, (3) a pledge to have their child vaccinated, (4) information salience through links to guidelines and vaccine safety information.
Number of subjects: 2076
Study 38367966 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 2076
Study 38367972 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-annual ultrasound (US) and abbreviated liver MRI (AMRI)
Number of subjects: 944
Study 38367972 — intervention group
Group type: COMPARATOR
Intervention: Semi-annual ultrasound (US) alone
Number of subjects: 944
Study 38367973 — intervention group
Group type: EXPERIMENTAL
Intervention: baby HABIT-ILE intervention (50 hours over 2 weeks)
Number of subjects: 48
Study 38367973 — intervention group
Group type: COMPARATOR
Intervention: baby HABIT-ILE intervention (after 3-month assessment)
Number of subjects: 48
Study 38368175 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D flow MRI
Number of subjects: 64
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing anal incontinence (AI)
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Passed or ongoing episodes of AI
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life impact due to AI
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-obstetrical AI ≥ 6 months (POAI ≥ 6)
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental birth as a protective factor for POAI ≥ 6
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity as a risk factor for POAI ≥ 6
Number of subjects: 227
Study 38368278 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI as a risk factor for POAI ≥ 6
Number of subjects: 227
Study 38368316 — intervention group
Group type: EXPERIMENTAL
Intervention: Online video-assisted education on breastfeeding
Number of subjects: 80
Study 38368316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 38368355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clip-reconstruction
Number of subjects: 880
Study 38368355 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 880
Study 38368355 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular care during hospital stay
Number of subjects: 880
Study 38368409 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare tip soft coagulation (STSC) of the entire resection margin after EMR
Number of subjects: 306
Study 38368409 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 306
Study 38368409 — intervention group
Group type: EXPERIMENTAL
Intervention: Snare tip soft coagulation (STSC)
Number of subjects: 306
Study 38368495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-modified albumin (IMA)
Number of subjects: 113
Study 38368518 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-thaw extended culture blastocysts
Number of subjects: 182
Study 38368518 — intervention group
Group type: COMPARATOR
Intervention: Thawed cleavage-stage ET
Number of subjects: 182
Study 38368603 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week)
Number of subjects: 30
Study 38368603 — intervention group
Group type: COMPARATOR
Intervention: Daily GH (0.034 mg/kg/day)
Number of subjects: 30
Study 38368603 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week) after continuous treatment
Number of subjects: 30
Study 38368603 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (0.16 mg/kg/week) after switch from daily GH
Number of subjects: 30
Study 38368603 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan
Number of subjects: 30
Study 38368846 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 475
Study 38368901 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted anticoagulation according to TRiP(cast) score (no prescription if score <7, anticoagulation if score ≥7)
Number of subjects: 1505
Study 38368901 — intervention group
Group type: COMPARATOR
Intervention: Control phase (anticoagulation prescription according to physician's usual practice)
Number of subjects: 1505
Study 38369126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (E-EN)
Number of subjects: 314
Study 38369126 — intervention group
Group type: COMPARATOR
Intervention: Early supplemental parenteral nutrition (E-SPN)
Number of subjects: 314
Study 38369221 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 98
Study 38369221 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 98
Study 38369233 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral thiamine (100 mg daily) for ≥3 days
Number of subjects: 449
Study 38369233 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 449
Study 38369238 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage blood pressure measurements
Number of subjects: 130
Study 38369267 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week interdisciplinary weight loss and lifestyle intervention
Number of subjects: 89
Study 38369528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate solution (RAS)
Number of subjects: 143
Study 38369528 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 143
Study 38369528 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS-only
Number of subjects: 143
Study 38369528 — intervention group
Group type: COMPARATOR
Intervention: NSS-only
Number of subjects: 143
Study 38369573 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV-101 (low dose)
Number of subjects: 32
Study 38369573 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV-101 (high dose)
Number of subjects: 32
Study 38369573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 38369573 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV-101 (low dose and high dose)
Number of subjects: 32
Study 38369805 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment (not specified, but includes proteasome inhibitor-based combination therapy)
Number of subjects: 45
Study 38369805 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteasome inhibitor (PI)-based combination therapy
Number of subjects: 45
Study 38369805 — intervention group
Group type: COMPARATOR
Intervention: Second BCMA CAR-T (including LCAR-B38M)
Number of subjects: 45
Study 38369805 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 45
Study 38369805 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage therapy in patients with extramedullary disease at baseline
Number of subjects: 45
Study 38369951 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 188
Study 38370154 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella
Number of subjects: 0
Study 38370154 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP
Number of subjects: 0
Study 38370154 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38370536 — intervention group
Group type: COMPARATOR
Intervention: Moderate-increasing BMI trajectory
Number of subjects: 1824
Study 38370536 — intervention group
Group type: COMPARATOR
Intervention: High-increasing BMI trajectory
Number of subjects: 1824
Study 38370536 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI variability (measured by standard deviation)
Number of subjects: 1824
Study 38370630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60
Study 38370630 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with semantic feature analysis (SFA)
Number of subjects: 60
Study 38370630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar tDCS
Number of subjects: 60
Study 38370630 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 38371194 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 159
Study 38371194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159